Copenhagen, Denmark & New York, USA – [Date of Publication] – Genmab, a global biotechnology company, is set to initiate discussions with global regulatory agencies following compelling interim Phase III data for its investigational bispecific antibody, petosemtamab. The drug, when used in combination with Merck & Co.’s Keytruda (pembrolizumab), has demonstrated a remarkable 50% reduction in the risk of death for patients with first-line (1L) PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This breakthrough, revealed from the ongoing LiGeR-HN1 trial, has been met with significant enthusiasm from analysts and investors, signaling a potential paradigm shift in the treatment landscape for this challenging disease.
A Beacon of Hope: Groundbreaking Data Emerges from LiGeR-HN1 Trial
The pivotal Phase III LiGeR-HN1 trial, an open-label study involving 699 patients, pitted petosemtamab, a novel IgG1-bispecific antibody targeting both epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with Keytruda, against Keytruda monotherapy. The initial interim analysis, meticulously reviewed by an independent data monitoring committee (IDMC), unveiled statistically significant and clinically meaningful improvements in both overall survival (OS) and objective response rate (ORR).
The combination therapy achieved a dual primary endpoint, reducing the risk of death by an impressive 50% and demonstrating an odds ratio of 3.17 for ORR. Crucially, these benefits were observed irrespective of the patients’ human papillomavirus (HPV) status, a factor that has historically presented challenges and uncertainties in HNSCC treatment. This broad efficacy across different patient subgroups marks a significant advancement.
The safety profile of the petosemtamab and Keytruda combination was reported as generally well-tolerated, aligning with the known safety profiles of the individual agents. This favorable safety data further enhances the appeal of the combination as a viable therapeutic option.
Chronology of a Promising Development
Genmab’s journey with petosemtamab has been marked by strategic development and a commitment to addressing unmet needs in oncology. The initiation of the LiGeR-HN1 trial was a critical step in validating the potential of this bispecific antibody in a large and complex patient population. The successful completion of the first interim analysis and the subsequent positive findings have accelerated the path towards regulatory engagement.
- [Date of Trial Initiation – Hypothetical]: The LiGeR-HN1 Phase III trial (NCT06525220) is initiated, enrolling patients with first-line PD-L1-positive recurrent/metastatic HNSCC.
- [Date of First Interim Analysis – Hypothetical]: An independent data monitoring committee (IDMC) conducts the first interim analysis of the LiGeR-HN1 trial.
- [Present Date]: Genmab announces positive topline results from the first interim analysis, revealing a 50% reduction in the risk of death and a significant improvement in ORR.
- [Present Date]: Genmab confirms plans to engage with global regulatory authorities based on these compelling interim findings.
- [Future Date]: Full data from the LiGeR-HN1 trial is expected to be presented at an upcoming medical meeting.
Beyond the first-line setting, Genmab is actively investigating petosemtamab in other crucial areas. The Phase III LiGeR-HN2 study (NCT06496178) is exploring its efficacy in patients with second- and third-line recurrent/metastatic HNSCC. Furthermore, the company is advancing petosemtamab in the fight against colorectal cancer, with two Phase III studies, LiGeR-CRC1 (NCT07702032) and LiGeR-CRC2 (NCT07775287), evaluating its potential in patients with previously treated, recurrent, unresectable, or metastatic colorectal cancer.
The recent US approval of Keytruda on June 12, 2025, for the neoadjuvant and adjuvant treatment of resectable locally advanced HNSCC expressing PD-L1, further underscores the significance of the PD-L1 pathway in this disease and highlights the evolving therapeutic landscape where combinations like petosemtamab and Keytruda are poised to play a crucial role.
The timing of Genmab’s announcement also coincides with a period of significant activity in HNSCC research. Just three days prior, Johnson & Johnson’s (J&J) Rybrevant Faspro combination demonstrated success in a similar patient population, with data presented at the European Society of Medical Oncology (ESMO) Congress 2026. This underscores the intense focus and ongoing progress within the HNSCC therapeutic arena.
Supporting Data: Unpacking the Clinical Significance
The LiGeR-HN1 trial’s results are underpinned by robust statistical and clinical metrics. The 50% reduction in the risk of death represents a substantial improvement in overall survival, offering patients a significantly extended lifespan. The odds ratio of 3.17 for objective response rate signifies a nearly threefold increase in the likelihood of achieving a measurable reduction in tumor size when treated with the combination therapy compared to Keytruda alone.
The significance of achieving these dual primary endpoints at the first interim analysis cannot be overstated. It suggests that the combination therapy is not only effective but also delivers its benefits relatively early in the treatment course, which is critical for patients facing aggressive and life-limiting diseases. The independence of these findings from HPV status is particularly noteworthy. Historically, HPV-positive and HPV-negative HNSCC have exhibited different prognoses and responses to treatment. The demonstration of a consistent benefit across both groups broadens the applicability of petosemtamab plus Keytruda and simplifies treatment decisions.
The safety data, described as generally well-tolerated and consistent with individual agent profiles, is a crucial component for regulatory approval and physician adoption. A manageable safety profile is essential for a treatment intended for first-line therapy, where long-term treatment durability and patient quality of life are paramount.
Official Responses: A Call for Redefined Care
The clinical implications of the LiGeR-HN1 trial have resonated deeply within the medical community. Dr. Everett Vokes, Chair of the Department of Medicine and Physician-in-Chief at the University of Chicago Medicine, expressed his optimism and highlighted the transformative potential of this new combination.
"Patients with recurrent or metastatic head and neck cancer face a disease that can profoundly affect both survival and some of the most essential aspects of daily life, making progress in treatment urgently needed," stated Dr. Vokes. "As the first positive Phase III study in this patient population in several years, LiGeR-HN1 represents a major milestone with the potential to redefine care."
He further elaborated on the significance of meeting the dual primary endpoints, emphasizing the potential to revolutionize first-line treatment. "Meeting its dual primary endpoints of overall survival and objective response rate at the first interim analysis underscores the potential of petosemtamab plus Keytruda to transform first-line treatment for patients with PD-L1-positive disease, regardless of HPV status," Dr. Vokes added. "These results suggest this chemotherapy-free combination could reshape the treatment of this devastating disease by establishing a new therapeutic option."
The prospect of a chemotherapy-free regimen is particularly attractive. Chemotherapy can often be associated with significant side effects that impact patients’ quality of life. A combination therapy that achieves superior outcomes with a more favorable safety profile could significantly improve the patient experience and treatment adherence.
Implications and Market Reactions: A Strong Case for a New Standard of Care
The implications of these interim results are far-reaching, positioning Genmab for a significant impact on the HNSCC market. The company’s proactive approach in planning discussions with global regulatory authorities signals confidence in the data and a clear path towards potential approval.
The positive reception from the investment community further amplifies the significance of these findings. Analysts at William Blair described the results as "exceptional," highlighting the observed benefit irrespective of HPV status as a particularly noteworthy achievement that alleviates prior investor concerns. While acknowledging the anticipation for median OS, ORR, and progression-free survival (PFS) data, they remain steadfast in their assessment that the first interim analysis represents an "exceedingly positive top-line outcome." The analysts concluded that these results "meaningfully strengthen the case for petosemtamab plus Keytruda as the new standard-of-care regimen in 1L PD-L1+ HNSCC."
This strong endorsement from financial analysts has translated into tangible market performance for Genmab. On its primary listing on the Nasdaq Copenhagen, the company’s stock experienced a substantial surge of 29.06%, climbing from DKr2997.00 at the close of October 27 to DKr3868.00 by the close of October 28. A similar positive trend was observed on the New York Nasdaq, where Genmab’s stock rose by 28.25%, from $44.67 on October 27 to $57.29 on October 28. This market reaction underscores investor confidence in the drug’s potential and Genmab’s future prospects.
The successful development and potential approval of petosemtamab in combination with Keytruda could not only redefine the standard of care for first-line HNSCC but also solidify Genmab’s position as a leader in the development of innovative immuno-oncology therapies. The company’s ongoing commitment to advancing petosemtamab across various lines of therapy and indications, including colorectal cancer, further demonstrates a strategic vision to maximize the therapeutic potential of this promising bispecific antibody. As Genmab prepares to engage with global regulators, the oncology community eagerly awaits the full data presentation and the subsequent steps towards bringing this potentially life-altering treatment to patients.
About the Author
